-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media Release
TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
-
Media Release
TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
-
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
-
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US